Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study

American Heart Journal

Volumn 139, Issue 4, 2000, Pages 563-566

  Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034079664     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90031-0     Document Type: Article

References (19)

1. 1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-8.
2. 2. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16:11-5.
3. 3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
4. 4. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990;82:17-26.
5. 5. The PARAGON investigators. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation 1998;97:2386-95.
6. 6. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-505.
7. 7. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
8. 8. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-63.
9. 9. Moliterno DJ, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In: Lincoff A, Topol E, editors. Contemporary cardiology: platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Totowa (NJ): Humana Press; 1999. 201-27.
10. 10. The IMPACT-II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
11. 11. Steiner B, Hofer U, Wittke B, et al. Plasma concentrations of lamifiban and glycoprotein IIb/IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A [abstract]. Eur Heart J 1998;19:598.
12. 12. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphallbbeta3) inhibitors. Blood 1998;92: 3240-9.
13. 13. Steiner B, Hofer U, Wittke B, et al. Plasma level of lamifiban and platelet receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A [abstract]. Circulation 1998;98:1-561.
14. 14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum. Nephron 1976;16:31-41.
15. 15. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;2276:811-5.
16. 16. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
17. 17. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-6.
18. 18. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391-5.
19. 19. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999;100:1977-82.